Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Electrochemotherapy for Breast Cancer-Results From the INSPECT Database

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Matthiessen, LW, Keshtgar, M, Curatolo, P, Kunte, C, Grischke, E-M, Odili, J, Muir, T, Mowatt, D, Clover, JP, Liew, SH, Dahlstroem, K, Newby, J, Letulé, V, Stauss, E, Humphreys, A, Banerjee, S, Klein, A, Rotunno, R, de Terlizzi, F & Gehl, J 2018, 'Electrochemotherapy for Breast Cancer-Results From the INSPECT Database' Breast Cancer: Basic and Clinical Research, bind 18, nr. 5, s. e909-e917. https://doi.org/10.1016/j.clbc.2018.03.007

APA

CBE

Matthiessen LW, Keshtgar M, Curatolo P, Kunte C, Grischke E-M, Odili J, Muir T, Mowatt D, Clover JP, Liew SH, Dahlstroem K, Newby J, Letulé V, Stauss E, Humphreys A, Banerjee S, Klein A, Rotunno R, de Terlizzi F, Gehl J. 2018. Electrochemotherapy for Breast Cancer-Results From the INSPECT Database. Breast Cancer: Basic and Clinical Research. 18(5):e909-e917. https://doi.org/10.1016/j.clbc.2018.03.007

MLA

Vancouver

Author

Matthiessen, Louise Wichmann ; Keshtgar, Mohammed ; Curatolo, Pietro ; Kunte, Christian ; Grischke, Eva-Maria ; Odili, Joy ; Muir, Tobian ; Mowatt, David ; Clover, James P ; Liew, Se Hwang ; Dahlstroem, Karin ; Newby, Jackie ; Letulé, Valerie ; Stauss, Eva ; Humphreys, Alison ; Banerjee, Shramana ; Klein, Annette ; Rotunno, Roberta ; de Terlizzi, Francesca ; Gehl, Julie. / Electrochemotherapy for Breast Cancer-Results From the INSPECT Database. I: Breast Cancer: Basic and Clinical Research. 2018 ; Bind 18, Nr. 5. s. e909-e917.

Bibtex

@article{ee42df7835c4442b9caf35464c93ea02,
title = "Electrochemotherapy for Breast Cancer-Results From the INSPECT Database",
abstract = "BACKGROUND: Cutaneous recurrence from breast cancer can pose a clinical challenge. It might be the only disease site, or could be part of disseminated disease, and often profoundly affects quality of life. Electrochemotherapy is a palliative treatment using electric pulses to locally permeabilize tumor cells and thereby significantly increase bleomycin cytotoxicity. Collaborating with the International Network for Sharing Practice on ElectroChemoTherapy (INSPECT), we consecutively and prospectively accrued data on patients treated with electrochemotherapy for cutaneous metastases from breast cancer.PATIENTS AND METHODS: Patients were treated with electrochemotherapy at 10 European centers. Under either local or general anaesthesia patients were treated with either local injection (1000 IU/mL intratumoral) or systemic infusion (15,000 IU/m2) of bleomycin.RESULTS: One hundred nineteen patients were included at 10 institutions in the INSPECT network. The primary location was the chest (89{\%}), the median diameter of the cutaneous metastases was 25 mm. Ninety patients were available for response evaluation after 2 months. Complete response was observed in 45 patients (50{\%}), partial response in 19 (21{\%}), stable disease in 16 (18{\%}), and progressive disease in 7 (8{\%}). Three patients were not evaluable. Common side effects were ulceration, long-lasting hyperpigmentation, and low-grade pain. No serious adverse events were observed.CONCLUSION: Electrochemotherapy showed high response rates after a single treatment. Electrochemotherapy has few side effects and can be used as an adjunct to systemic therapies or as a solo treatment. We therefore recommend considering electrochemotherapy for patients with cutaneous metastases.",
author = "Matthiessen, {Louise Wichmann} and Mohammed Keshtgar and Pietro Curatolo and Christian Kunte and Eva-Maria Grischke and Joy Odili and Tobian Muir and David Mowatt and Clover, {James P} and Liew, {Se Hwang} and Karin Dahlstroem and Jackie Newby and Valerie Letul{\'e} and Eva Stauss and Alison Humphreys and Shramana Banerjee and Annette Klein and Roberta Rotunno and {de Terlizzi}, Francesca and Julie Gehl",
note = "Copyright {\circledC} 2018 Elsevier Inc. All rights reserved.",
year = "2018",
month = "10",
doi = "10.1016/j.clbc.2018.03.007",
language = "English",
volume = "18",
pages = "e909--e917",
journal = "Breast Cancer: Basic and Clinical Research",
issn = "1178-2234",
publisher = "Libertas Academica Ltd",
number = "5",

}

RIS

TY - JOUR

T1 - Electrochemotherapy for Breast Cancer-Results From the INSPECT Database

AU - Matthiessen, Louise Wichmann

AU - Keshtgar, Mohammed

AU - Curatolo, Pietro

AU - Kunte, Christian

AU - Grischke, Eva-Maria

AU - Odili, Joy

AU - Muir, Tobian

AU - Mowatt, David

AU - Clover, James P

AU - Liew, Se Hwang

AU - Dahlstroem, Karin

AU - Newby, Jackie

AU - Letulé, Valerie

AU - Stauss, Eva

AU - Humphreys, Alison

AU - Banerjee, Shramana

AU - Klein, Annette

AU - Rotunno, Roberta

AU - de Terlizzi, Francesca

AU - Gehl, Julie

N1 - Copyright © 2018 Elsevier Inc. All rights reserved.

PY - 2018/10

Y1 - 2018/10

N2 - BACKGROUND: Cutaneous recurrence from breast cancer can pose a clinical challenge. It might be the only disease site, or could be part of disseminated disease, and often profoundly affects quality of life. Electrochemotherapy is a palliative treatment using electric pulses to locally permeabilize tumor cells and thereby significantly increase bleomycin cytotoxicity. Collaborating with the International Network for Sharing Practice on ElectroChemoTherapy (INSPECT), we consecutively and prospectively accrued data on patients treated with electrochemotherapy for cutaneous metastases from breast cancer.PATIENTS AND METHODS: Patients were treated with electrochemotherapy at 10 European centers. Under either local or general anaesthesia patients were treated with either local injection (1000 IU/mL intratumoral) or systemic infusion (15,000 IU/m2) of bleomycin.RESULTS: One hundred nineteen patients were included at 10 institutions in the INSPECT network. The primary location was the chest (89%), the median diameter of the cutaneous metastases was 25 mm. Ninety patients were available for response evaluation after 2 months. Complete response was observed in 45 patients (50%), partial response in 19 (21%), stable disease in 16 (18%), and progressive disease in 7 (8%). Three patients were not evaluable. Common side effects were ulceration, long-lasting hyperpigmentation, and low-grade pain. No serious adverse events were observed.CONCLUSION: Electrochemotherapy showed high response rates after a single treatment. Electrochemotherapy has few side effects and can be used as an adjunct to systemic therapies or as a solo treatment. We therefore recommend considering electrochemotherapy for patients with cutaneous metastases.

AB - BACKGROUND: Cutaneous recurrence from breast cancer can pose a clinical challenge. It might be the only disease site, or could be part of disseminated disease, and often profoundly affects quality of life. Electrochemotherapy is a palliative treatment using electric pulses to locally permeabilize tumor cells and thereby significantly increase bleomycin cytotoxicity. Collaborating with the International Network for Sharing Practice on ElectroChemoTherapy (INSPECT), we consecutively and prospectively accrued data on patients treated with electrochemotherapy for cutaneous metastases from breast cancer.PATIENTS AND METHODS: Patients were treated with electrochemotherapy at 10 European centers. Under either local or general anaesthesia patients were treated with either local injection (1000 IU/mL intratumoral) or systemic infusion (15,000 IU/m2) of bleomycin.RESULTS: One hundred nineteen patients were included at 10 institutions in the INSPECT network. The primary location was the chest (89%), the median diameter of the cutaneous metastases was 25 mm. Ninety patients were available for response evaluation after 2 months. Complete response was observed in 45 patients (50%), partial response in 19 (21%), stable disease in 16 (18%), and progressive disease in 7 (8%). Three patients were not evaluable. Common side effects were ulceration, long-lasting hyperpigmentation, and low-grade pain. No serious adverse events were observed.CONCLUSION: Electrochemotherapy showed high response rates after a single treatment. Electrochemotherapy has few side effects and can be used as an adjunct to systemic therapies or as a solo treatment. We therefore recommend considering electrochemotherapy for patients with cutaneous metastases.

U2 - 10.1016/j.clbc.2018.03.007

DO - 10.1016/j.clbc.2018.03.007

M3 - Journal article

VL - 18

SP - e909-e917

JO - Breast Cancer: Basic and Clinical Research

JF - Breast Cancer: Basic and Clinical Research

SN - 1178-2234

IS - 5

ER -

ID: 56562857